"The voice for cancer physicians and their patients in Massachusetts."

FDA approves azacitidine tablets (Onureg) for acute myeloid leukemia

08 Sep 2020 8:12 AM | Nathan Strunk

The U.S. Food and Drug Administration approved azacitidine tablets (ONUREGĀ®, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c)


P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: msco@mms.org
Powered by Wild Apricot Membership Software